Beta thalassemia: new therapeutic options beyond transfusion and iron chelation I Motta, R Bou-Fakhredin, AT Taher, MD Cappellini Drugs 80, 1053-1063, 2020 | 86 | 2020 |
Non-transfusion-dependent thalassemia: an update on complications and management J Sleiman, A Tarhini, R Bou-Fakhredin, AN Saliba, MD Cappellini, ... International journal of molecular sciences 19 (1), 182, 2018 | 76 | 2018 |
Gadolinium and multiple sclerosis: vessels, barriers of the brain, and glymphatics C Saade, R Bou-Fakhredin, DM Yousem, K Asmar, L Naffaa, F El-Merhi American Journal of Neuroradiology 39 (12), 2168-2176, 2018 | 54 | 2018 |
2021 update on clinical trials in β‐thalassemia KM Musallam, R Bou‐Fakhredin, MD Cappellini, AT Taher American journal of hematology 96 (11), 1518-1531, 2021 | 51 | 2021 |
Care of patients with hemoglobin disorders during the COVID‐19 pandemic: An overview of recommendations AT Taher, R Bou‐Fakhredin, F Kreidieh, I Motta, L De Franceschi, ... American Journal of Hematology 95 (8), E208, 2020 | 38 | 2020 |
Deferasirox: over a decade of experience in thalassemia NM Moukalled, R Bou-Fakhredin, AT Taher Mediterranean Journal of Hematology and Infectious Diseases 10 (1), 2018 | 36 | 2018 |
Revisiting beta thalassemia intermedia: past, present, and future prospects N Ben Salah, R Bou-Fakhredin, F Mellouli, AT Taher Hematology 22 (10), 607-616, 2017 | 36 | 2017 |
Hypercoagulability and vascular disease AT Taher, MD Cappellini, R Bou-Fakhredin, D Coriu, KM Musallam Hematology/Oncology Clinics 32 (2), 237-245, 2018 | 35 | 2018 |
Thalassemia and malignancy: An emerging concern? MH Hodroj, R Bou-Fakhredin, W Nour-Eldine, HA Noureldine, ... Blood reviews 37, 100585, 2019 | 32 | 2019 |
Iron overload and chelation therapy in non-transfusion dependent thalassemia R Bou-Fakhredin, AH Bazarbachi, B Chaya, J Sleiman, MD Cappellini, ... International Journal of Molecular Sciences 18 (12), 2778, 2017 | 32 | 2017 |
Insights into the diagnosis and management of iron deficiency in inflammatory bowel disease R Bou-Fakhredin, R Halawi, J Roumi, A Taher Expert review of hematology 10 (9), 801-808, 2017 | 26 | 2017 |
Pharmacological induction of fetal hemoglobin in β-thalassemia and sickle cell disease: An updated perspective R Bou-Fakhredin, L De Franceschi, I Motta, MD Cappellini, AT Taher Pharmaceuticals 15 (6), 753, 2022 | 25 | 2022 |
Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies AT Taher, R Bou-Fakhredin, A Kattamis, V Viprakasit, MD Cappellini Expert Review of Hematology 14 (10), 897-909, 2021 | 25 | 2021 |
Thalassemia in the emergency department: special considerations for a rare disease AN Saliba, A Atoui, M Labban, H Hamade, R Bou-Fakhredin, A Mufarrij, ... Annals of Hematology 99, 1967-1977, 2020 | 20 | 2020 |
Circulating microparticles and the risk of thromboembolic events in Egyptian beta thalassemia patients I Youssry, N Soliman, M Ghamrawy, RM Samy, A Nasr, M Abdel Mohsen, ... Annals of hematology 96, 597-603, 2017 | 19 | 2017 |
Deep venous thrombosis and pulmonary embolism after COVID-19 mRNA vaccination A Atoui, K Jarrah, L Al Mahmasani, R Bou-Fakhredin, AT Taher Annals of Hematology 101 (5), 1111-1113, 2022 | 17 | 2022 |
Emerging therapies in β-thalassemia: toward a new era in management R Bou-Fakhredin, R Tabbikha, H Daadaa, AT Taher Expert Opinion on Emerging Drugs 25 (2), 113-122, 2020 | 17 | 2020 |
Cardiovascular complications in β-thalassemia: getting to the heart of it N Akiki, MH Hodroj, R Bou-Fakhredin, K Matli, AT Taher Thalassemia Reports 13 (1), 38-50, 2023 | 16 | 2023 |
COVID-19 in benign hematology: emerging challenges and special considerations for healthcare professionals P Noun, A Ibrahim, MH Hodroj, R Bou-Fakhredin, AT Taher Expert Review of Hematology 13 (10), 1081-1092, 2020 | 15 | 2020 |
Recommendations for pregnancy in rare inherited anemias AT Taher, A Iolascon, CF Matar, R Bou-Fakhredin, L de Franceschi, ... Hemasphere 4 (4), e446, 2020 | 14 | 2020 |